会員専用ページ
法人概要
お問い合わせ
事業案内
事業案内

ホーム ＞ 事業案内 ＞ 臨床研究開発部

臨床研究開発部

臨床研究・開発部では、臨床研究および治療法の開発などを行います。
特に非アルコール性脂肪性肝疾患（NAFLD）に関しては、全国の多施設共同研究グループJapan Study Group of NAFLD（JSG-NAFLD）を組織し、多くの業績を蓄積しています。
協賛企業との連携により、機能性食品の開発も行います。

横浜市立大学大学院医学研究科 肝胆膵消化器病学教室 主任教授
中島 淳 -なかじまあつし-
中島 淳

略歴

1989年 大阪大学卒業
4年社会保険中央総合病院内科
1994年 茅ヶ崎市立病院
1997年 東京大学第三内科助手
1998年 ハーバード大学客員研究員
2014年 横浜市立大学大学院医学研究科 肝胆膵消化器病学教室主任教授
  • 非アルコール性脂肪肝疾患（NAFLD）ガイドライン作成メンバー
  • 論文業績 英語論文550報
  • 最近5年間の論文抜粋
  • Clinical Gastroenterology and Hepatology, 2019（アジア11か国とのNAFLD診断におけるエラストグラフィーの有用性の国際共同研究）
  • Clinical Gastroenterology and Hepatology, 2018（メイヨークリニック放射線科とのMRE共同試験）
  • Lancet Oncology. 2016（メトフォルミンによる大腸発がん予防の第3相試験）
  • Gastroenterology. 2016（MRエラストグラフィーによるNASH非侵襲的診断臨床研究）
  • Nature. 2014（粘膜免疫の基礎研究）
  • Cell Metab. 2012（エンドトキシン肝臓の感受性亢進に関する基礎研究）

テレビ出演など

NHKスペシャル、ためしてガッテン、ガッテン、タケシの家庭の医学、世界一受けたい授業、BS夢の扉、今日の健康（多数）など

Publications

    • [58] Kamda Y, Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, Tobita H, Tsutsumi T, Akahane T, Hasebe A, Kawanaka M, Kessoku T, Eguchi Y, Syokita H, Nakajima A, Kamada T, Yoshiji H, Kawaguchi T, Sakugawa H, Morishita A, Masaki T, Ohmura T, Watanabe T, Yoda Y, Enomoto N, Ono M, Fuyama K, Okada K, Nishimoto N, Ito YM, Takahashi H, Sumida Y, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Clinical characteristics of steatotic liver disease categories in a large cohort of Japanese health checkup participants. Gastro Hep Advances in press. doi: 10.1016/j.gastha.2024.08.006
    • [57] Nouso K, Kawanaka M, Fujii H, Kariyama K, Toyoda H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Kumada T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD). Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease. Hepatol Res. 2024 Apr 25. doi: 10.1111/hepr.14039. Epub ahead of print. PMID: 38661715.
    • [56] TsuTsumi T, Kawaguchi T, Fujii H, Kamada Y, Takahashi H, Kawanaka M, Sumida Y, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Nakajima A, Okanoue T. Hepatic Inflammation and Fibrosis are Profiles Related to Mid-Term Mortality in Biopsy-Proven MASLD: A Multicenter Study in Japan. Aliment Pharmacol Ther. 2024 Jun;59(12):1559-1570. doi: 10.1111/apt.17995. Epub 2024 Apr 23. PMID: 38651312.
    • [55] Takahashi, et al. Serum Cytokeratin 18 Fragment is an Indicator for Treating Metabolic Dysfunction-associated Steatotic Liver Disease,. Gastro hep Advances. In press.
    • [54] Toyoda H, Fujii H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Kawanaka M,Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito　M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M,　Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, the Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of noninvasive markers for HCC risk stratification in 1,389 patients with biopsy-proven NAFLD. Gastro Hep Advances(2023), doi: https://doi.org/10.1016/j.gastha.2023.07.018.
    • [53] Arai T, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
    • [52] Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study. Clin Mol Hepatol in press
    • [51] Miura K, Hayashi H, Kamada Y, Fujii H, Takahashi H, Oeda S, Iwaki M, Kawaguchi T, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease. Hepatol Res. 2023 Oct;53(10):978-988.
    • [50] Ishiba H, Sumida Y, Kamada Y, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Takahashi H, Ueda S, Aishima S, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Noninvasive tests predict liver-related events and mortality in patients with non-alcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study. J Gastroenterol Hepatol. In press
    • [49] Hirokazu Takahashi, Miwa Kawanaka, Hideki Fujii *, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguch, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Shinichiro Ueda, Atsushi Nakajima, Yoshio Sumida, Takeshi Olanoue

Association of Serum Albumin Levels and Long-term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease. Nutrients in press

  • [48] Fujii H, Takahashi H, Kamada Y, Sumida Y, Nakajima A. Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma. JHEP Reports in press
  • [47] Hayashi H, Kamada Y*, Fujii H, Takahashi H, Oeda S, Iwaki M, Kawaguchi T, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. Ultrasound Med Biol 2023 Apr 27:S0301-5629(23)00109-6.
  • [46] Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, Ikegami T, Fujii H, Toyoda H, Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanoue T, Nakajima A, Takahashi H. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease. Hepatol Res in press
  • [45] Fujii H, Fujii M, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease. Hepatol Res. 2023 May;53(5):391-400.
  • [44] Seko Y, Takahashi H, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study. Hepatol Res. 2023 Apr;53(4):312-321.
  • [43] Kamada Y, Nakamura T, Isobe S, Hosono K, Suama Y, Ohtakaki Y, Nauchi A, Yasuda N, Mitsuta S, Miura K, Yamamoto T, Hosono T, Yoshida A, Kawanishi I, Fukushima H, Kinoshita M, Umeda A, Kinoshita Y, Fukami K, Miyawaki T, Fujii H, Yoshida Y, Kawanaka M, Hyogo H, Morishita A, Hayashi H, Tobita H, Tomita K, Ikegami T, Takahashi H, Yoneda M, Jun DW, Sumida Y, Okanoue T, Nakajima A; JANIT Forum. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. J Gastroenterol. 2023 Feb;58(2):79-97.
  • [42] Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupșor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yılmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022 May;71(5):1006-1019.
  • [41] Kamada Y, Munekage K, Nakahara T, Fujii H, Sawai Y, Doi Y, Hyogo H, Sumida Y, Imai Y, Miyoshi E, Ono M; Japan Study Group of NAFLD (JSG-NAFLD). The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD. Nutrients. 2022 Dec 23;15(1):66.
  • [40] Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia. J Gastroenterol Hepatol. 2022 Oct 5. doi: 10.1111/jgh.16019. Epub ahead of print. PMID: 36198983.
  • [39] Kamada Y, Takahashi H, Ogawa Y, Hyogo H, Nakamura K, Yada T, Asada N, Bando T, Sawano H, Hatanaka M, Tosa T, Ando M, Hikita E, Yoshida K, Koseki M, Sumida Y, Maeda K, Fujii M, Aishima S, Hayakawa M, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Characterization of Nutrient Intake in Biopsy-Confirmed NAFLD Patients. Nutrients. 2022 Aug 23;14(17):3453. doi: 10.3390/nu14173453. PMID: 36079715; PMCID: PMC9460347.
  • [38] Kamada Y, Takahashi H, Shimizu M, Kawaguchi T, Sumida Y, Fujii H, Seko Y, Fukunishi S, Tokushige K, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG‐NAFLD). Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol. 2021 Dec;56(12):1045-1061. doi: 10.1007/s00535-021-01833-9. Epub 2021 Oct 31. PMID: 34718870.
  • [37] Hideki Fujii, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyota, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Sakura Yamamura, Koji Sawada14,15, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito18, Asuka Araki17, Shingo Arakaki,Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Norifumi Kawada, Akihiro Tokushige,Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD) Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study Clin Gastroenterol Hepatol, in press.
  • [36] Kamada Y, Takahashi H, Shimizu M, Kawaguchi T, Sumida Y, Fujii H, Seko Y, Fukunishi S, Tokushige K, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG‐NAFLD). Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol. 2021 Oct 31. doi: 10.1007/s00535-021-01833-9. Epub ahead of print. PMID: 34718870.
  • [35] Sumida Y, Yoneda M, Seko Y, Takahashi H, Hara N, Fujii H, Itoh Y, Yoneda M, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG-NAFLD). Role of vitamin E in the treatment of non-alcoholic steatohepatitis. Free Radic Biol Med. 2021 Oct 26:S0891-5849(21)00767-X. doi: 10.1016/j.freeradbiomed.2021.10.017. Epub ahead of print. PMID: 34715296.
  • [34] Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Japan Study Group of NAFLD. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life. 2021; 11(2):143. https://doi.org/10.3390/life11020143
  • [33] Ishiba Y, Sumida Y, Tanaka S, Yoneda, M., Hyogo, H., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Yoneda, M., et al; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD). Type IV collagen 7S is the most accurate test to identify advanced fibrosis in NAFLD with type 2 diabetes. Hepatol Commun in press
  • [32] Takahashi, H., Nakahara, T., Kogiso, T., Imajo, K., Kessoku, T., Kawaguchi, T., Ide, T., Kawanaka, M., Hyogo, H., Fujii, H., Ono, M., Kamada, Y., Sumida, Y., Anzai, K., Shimizu, M., Torimura, T., Nakajima, A., Tokushige, K., Chayama, K., Eguchi, Y. Japan Study Group of NAFLD (JSG-NAFLD). Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study. JGH Open, in press
  • [31] Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T , Hayashi H, Kobayashi T, Imajo K, Yoneda 7, Tada T, Kawaguchi T, Eguchi Y,hi Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A and Japan Study Group of NAFLD (JSG-NAFLD) Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease　 Diagnostics 2020, in press
  • [30] Yamamura S, Nakano N, Hashida R, Tsutsumi T, Kawaguchi K, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Zobair M Younossi ZM, Torimura T. Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH. J Gastroenterol Hepatol, in press
  • [29] Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Yoichi Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita T, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A and Japan Study Group of NAFLD (JSG-NAFLD). Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci, in press
  • [28] Fujii H, Kawada N; Japan Study Group of NAFLD (JSG-NAFLD)The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.Int. J. Mol. Sci. 2020, 21(11), 3863.
  • [27] Sumida Y, Yoneda M, Yoneda M, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opinion On Pharmacotherapy, in press.
  • [26] Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Automated quantification of fibrosis-related parameters (q-FPs) using dual-photon microscopy replace diagnosis of pathologists in NAFLD. Hepato Biliary Surgery and Nutrition, in press.
  • ［25］ Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Atsushi Nakajima; Japan Study Group of NAFLD (JSG-NAFLD). Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Inter J Mol Sci 2020;21 (6),1907.
  • ［24］ Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease. Diab Res. 2020 Mar 05;2(S1):17-25.
  • ［23］ Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Estimated Prevalence of Advanced Hepatic Fibrosis by Elastography in Patients with Type 2 Diabetes. Interventions Obes Diabetes 3(3). IOD.000570.2020. DOI: 10.31031/IOD.2020.03.000570
  • ［22］ Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Antidiabetic Treatments for Diabetes with Liver Cirrhosis. Interventions Obes Diabetes 3(3). IOD.000566.2020. DOI: 10.31031/IOD.2020.03.000566
  • ［21］ Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res. 2019 Nov;49(11):1256-1262. doi: 10.1111/hepr.13425. Epub 2019 Oct 25.
  • ［20］ Sumida Y, Yoneda M, Okanoue T; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD). Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD? J Gastroenterol. 2019 May;54(5):474-475.
  • ［19］ Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Eguchi Y, Chayama K, Nakajima A, Nishimoto N, Kawada N; Japan Study Group of Nonalcoholic Fatty Liver Disease. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019 Aug;34(8):1390-1395.
  • ［18］ Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Seko Y, Mori K, Kanemasa K, Shimada K, Imai S, Imajo K, Kawaguchi T, Nakajima A), Chayama K, Saibara T, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD). The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.J Gastroenterol. 2018 Nov;53(11):1216-1224. doi: 10.1007/s00535-018-1474-y. Epub 2018 May 9.
  • ［17］ Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M,Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K,Tanaka S(12), Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M,Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Sci Rep. 2018 Jul 11;8(1):10434. doi: 10.1038/s41598-018-28650-0.
  • ［16］ Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD). Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol Commun. 2017 Aug 16;1(8):780-791.
  • ［15］ Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017 Mar;47(4):266-280.
  • ［14］ Oeda S, Takahashi H, Yoshida H, Ogawa Y, Imajo K, Yoneda M, Koshiyama Y, Ono M, Hyogo H, Kawaguchi T, Fujii H, Nishino K, Sumida Y, Tanaka S, Kawanaka M, Torimura T, Saibara T, Kawaguchi A, Nakajima A, Eguchi Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prevalence of pruritus in patients with chronic liver disease: A multicenter study. Hepatol Res. 2017 Sep 6. doi:10.1111/hepr.12978. [Epub ahead of print] PubMed PMID: 28877392.
  • ［13］ Sumida Y, Nakajima A, Hyogo H, Tanaka S, Japan Study Group of NAFLD (JSG-NAFLD), et al. (2015) Non-invasive scoring systems for predicting NASH in Japan: evidences from Japan Study Group of NAFLD. Integr Mol Med 2: DOI: 10.15761/IMM.1000130
  • ［12］ Kessoku T, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Kawaguchi T, Nakajima A; Japan Study Group of NAFLD. Insulin resistance correlated with the severity of liver histology in Japanese NAFLD patients: a multicenter retrospective study. J Clin Gastroenterol. 2015 Feb;49(2):169-70.
  • ［11］ Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, Araki N, Tanaka K, Yamaguchi M, Matsuda Y, Ide Y, Otsuka T, Ozaki I, Ono N, Eguchi T, Anzai K; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015 Mar;45(3):269-78.
  • ［10］ Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi　T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, Saibara T, Sata M, Nakajima A, Itoh Y, Chayama K, Okanoue T; Japan Study Group of Nonalcoholic　Fatty Liver Disease. Type 2 diabetes mellitus is associated with the fibrosis　severity in patients with nonalcoholic fatty liver disease in a large　retrospective cohort of Japanese patients. J Gastroenterol. 2014　Nov;49(11):1477-84.
  • ［9］ Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG-NAFLD). Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol. 2014 Aug 7;20(29):10108-14.
  • ［8］ Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H,　Eguchi Y, Kanemasa K, Chayama K, Itoh Y, Yoshikawa T, Saibara T, Fujimoto K,　Nakajima A; Japan Study Group of NAFLD. The association of insomnia with　gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver　disease. J Gastroenterol. 2014 Jul;49(7):1163-74.
  • ［7］ Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, Saibara T, Anzai K, Eguchi Y; Japan Study Group of Non-alcoholic Fatty Liver Disease (JSG-NAFLD). Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. Hepatol Res. 2014　Nov;44(12):1196-207.
  • ［6］ Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y,　Kawaguchi T, Aoki N, Sata M, Kanemasa K, Kohgo Y, Saibara T, Chayama K, Itoh Y,　Yoshikawa T, Anzai K, Fujimoto K, Okanoue T, Nakajima A; Japan Study Group of　Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Noninvasive scoring systems in　patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol. 2013 Sep;48(9):1051-60.
  • ［5］ Kitajima Y, Hyogo H, Sumida Y, Eguchi Y, Ono N, Kuwashiro T, Tanaka K,　Takahashi H, Mizuta T, Ozaki I, Eguchi T, Kimura Y, Fujimoto K, Anzai K; Japan　Nonalcoholic Fatty Liver Disease Study Group (JSG-NAFLD). Severity of　non-alcoholic steatohepatitis is associated with substitution of adipose tissue　in skeletal muscle. J Gastroenterol Hepatol. 2013 Sep;28(9):1507-14.
  • ［4］ Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y,　Yoshikawa T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease　(JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012 Jan 5;12:2.
  • ［3］ Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T;JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty　liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012 May;47(5):586-95.
  • ［2］ Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, Suzuki Y, Aoki　N, Kanemasa K, Imajo K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y,　Yoshikawa T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease.　Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J　Gastroenterol. 2011 Nov;46(11):1300-6.
  • ［1］ Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y,　Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto　K, Kohgo Y, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease　(JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin,　and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty　liver disease. J Gastroenterol. 2011 Feb;46(2):257-68.

 

BUSINESS事業案内

医療経営戦略部
医療経営戦略部BUSINESS STRATEGY
臨床研究開発部
臨床研究開発部CLINICAL RESEARCH DEVELOPMENT
グローバル開発部
グローバル開発部GLOBAL STRATEGY
NASH療養指導士協会設立準備室
NASH療養指導士協会設立準備室NASH MEDICAL INSTRUCTOR